Advertisement
Canada markets close in 4 hours 19 minutes

  • S&P/TSX

    21,828.82
    +120.38 (+0.55%)
     

  • S&P 500

    4,993.85
    -17.27 (-0.34%)
     

  • DOW

    37,949.85
    +174.47 (+0.46%)
     

  • CAD/USD

    0.7277
    +0.0014 (+0.19%)
     

  • CRUDE OIL

    82.86
    +0.13 (+0.16%)
     

  • Bitcoin CAD

    88,670.74
    +1,115.57 (+1.27%)
     

  • CMC Crypto 200

    1,375.21
    +62.59 (+5.01%)
     

  • GOLD FUTURES

    2,407.40
    +9.40 (+0.39%)
     

  • RUSSELL 2000

    1,946.02
    +3.06 (+0.16%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,433.91
    -167.58 (-1.07%)
     

  • VOLATILITY

    18.64
    +0.64 (+3.56%)
     

  • FTSE

    7,894.94
    +17.89 (+0.23%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AFTER ISRAEL STRIKE-FUELLED TUMBLE

Apple pulls WhatsApp and Threads from China App Store

Stocks in play: Theratechnologies Inc.

Baystreet.ca

Announced that it obtained from the European Medicines Agency an additional month to address new questions received yesterday in regard to the establishment of a post-approval registry to gather long-term data on patients taking Trogarzo® (ibalizumab) in Europe. Theratechnologies will submit responses to the EMA by the end of June. The Committee for Medicinal Products for Human Use will then have 30 days to provide a recommendation to the European Union regarding the approval for the commercialization of Trogarzo® in Europe. Theratechnologies Inc. shares T.TH are trading down $0.03 at $5.93.